Purpose: Suprarenal fixation of aortic endografts appears to be a safe option in patients with a short or conical proximal aortic neck. However, concern persists regarding the long-term effect on renal function when renal artery ostia are crossed by the uncovered stent. We investigated the effect of suprarenal versus infrarenal endograft fixation on renal function and renal artery patency after endovascular aortic aneurysm repair. Methods: Records of 91 patients who underwent endovascular aortic aneurysm repair with a modular bifurcated stent graft between November 1999 and January 2002 were reviewed retrospectively. Two patients receiving dialysis because of chronic renal failure were excluded. Infrarenal fixation was used in 57 patients (group 1), and suprarenal fixation was used in 32 patients (group 2). In two patients in group 1 a Gianturco Z stent was inserted transrenally because of intraoperative proximal type I endoleak, and data for these patients were excluded from analysis. Follow-up evaluation was performed at 1, 6, and 12 months, and yearly thereafter, and included clinical assessment, measurement of serum creatinine concentration (SCr), and computed tomography angiography, per standard protocol. Median follow-up was 12 months (range, 1-36 months). Results: There was no statistically significant difference in patient demographic data, aneurysm size, or preoperative risk factors. Median SCr was significantly higher in group 2 (suprarenal fixation) than in group 1 (infrarenal fixation) preoperatively (1.2 mg/dL [range, 0.6-2.3 mg/dL] vs 0.9 mg/dL [range, 0.6-1.9 mg/dL], P ‫؍‬ .008) and at 1 month postoperatively (1.1 mg/dL [range, 0.8-5.6 mg/dL] vs 1.0 mg/dL [range, 0.6-2.1 mg/dL], P ‫؍‬ .045 ). There was a significant increase in median SCr in both groups at 1 month postoperatively (group 1, 1.0 mg/dL [range, 0.6-2.1  mg/dL], P ‫؍‬ .05; group 2, 1.1 mg/dL [range, 0.8-5.6 mg/dL] [mean SCr, 1.35 mg/dL vs 1.15 mg/dL, respectively] , P < .05). In group 1 SCr was increased significantly at 6 and 12 months (P < .001), whereas in group 2 SCr also increased at 6 and 12 months, but not significantly. The change in SCr over time was not significantly different between the two groups. In two of 32 patients in group 2, renal artery occlusion developed, associated with perfusion defects in renal parenchyma and persistently elevated SCr. Analysis of renal artery patency did not demonstrate any association between patency and treatment. No patient developed hypertension during follow-up. Conclusions: Suprarenal endograft fixation does not lead to significant renal dysfunction, and renal artery occlusion is uncommon within 12 months. A larger study with longer follow-up is essential to determine overall effects on renal function and renal artery patency. (J Vasc Surg 2003;37:1162-8.)
Endovascular aneurysm repair (EVAR) is gaining wider acceptance as a feasible alternative to conventional open repair, especially in patients at high risk. 1 Early results are promising; however, there remains concern regarding long-term durability compared with open repair. 2 In addition, the optimum endograft design and mechanism of aortic fixation remain to be determined, and a variety of devices are still under investigation. Successful EVAR requires secure fixation of the proximal end of the endograft to prevent stent-graft migration and proximal endoleak. Adverse morphologic features of the infrarenal aortic neck, eg, severe angulation, short neck length, cone shape, thrombus, or calcification, may adversely affect long-term durability of this minimally invasive technique. With these anatomic constraints, currently available commercial and investigational devices allow as many as 60% of all infrarenal abdominal aortic aneurysms (AAA) to be treated with EVAR. 3 To overcome the problem of unfavorable or suboptimal proximal neck, suprarenal endograft fixation has been proposed as a more secure form of proximal fixation and to increase the number of patients eligible for EVAR. Although many authors have reported the effectiveness and safety of suprarenal endograft fixation in studies with shortterm and intermediate follow-up, [4] [5] [6] [7] [8] [9] concern persists regarding the long-term effects on renal function and renal artery patency when the renal artery ostia are crossed by struts of the uncovered stent. Various devices were used in these studies, and the stent material used differed in construction and configuration, which may variably affect renal function and renal artery patency. We retrospectively evaluated our experience with suprarenal fixation of a single type of endograft, compared with infrarenal fixation of a single device, to determine its effect on renal function and renal artery patency.
PATIENTS AND METHODS
The records of 91 consecutive patients who underwent EVAR with a modular bifurcated endograft between November 1999 and January 2002 at our institution were reviewed. Over the same period, 19 additional patients underwent EVAR with an investigator-sponsored Investigational Device Exemptions aorto-monoiliac device and 68 patients underwent conventional open repair. Endovascular repair was offered to patients who had suitable AAA anatomy and were considered at high risk for open repair or when the patient requested endografting. Two patients receiving dialysis because of chronic renal failure before EVAR were excluded. Fifty-seven patients (group 1) received an endograft with infrarenal fixation (AneuRx; Medtronic, Santa Rosa, Calif). In two patients in this group a Gianturco Z stent was inserted to correct intraoperative proximal type I endoleak, and data for these patients were excluded from analysis; thus there were 55 patients in group 1. Group 2 consisted of 32 patients who underwent suprarenal endograft fixation with a Zenith stent graft (Cook, Bloomington, Ind) ( Fig 1) as part of a multicenter phase II trial of the US Food and Drug Administration. The two groups of patients received treatment within the same period. Anatomic criteria were used to determine the type of endograft to use. A proximal aortic neck diameter of Ͼ25 mm is not acceptable for the AneuRx endograft, and a proximal neck diameter of Յ28 mm is acceptable for the Zenith device. If the anatomy was suitable for both devices, the option of either endograft was offered to patients. Some patients preferred not to receive the study device because of the associated extensive follow-up. All operations were performed by two vascular surgeons (AGH and WAO), who are proficient in EVAR. The study was approved by the Mayo Foundation Institutional Review Board.
Baseline demographic data and preoperative risk factors, including hypertension, as defined by the Society for Vascular Surgery/American Association for Vascular Surgery reporting standard, 10 were obtained for all patients. Preoperative data recorded included aneurysm size and morphologic features, serum creatinine concentration (SCr), and obstructive renal artery disease documented with computed tomography (CT) angiography with multiplanar reconstruction or duplex ultrasound (US) scanning. Renal artery stenosis was further confirmed with intraoperative angiography. All patients underwent a standardized surveillance protocol that included physical examination (including blood pressure measurements), SCr determination, biplanar abdominal plain radiography, and CT angiography at 1, 6, and 12 months and annually thereafter. All intraoperative completion arteriograms and postoperative CT angiograms were examined to identify any endoleaks, confirm patency of the stent graft and renal arteries, and note presence of renal infarction. Duplex US scanning and digital subtraction arteriography were performed if additional information was needed or the CT scan was inadequate. Duplex US scanning was performed by certified vascular technicians using standardized criteria to determine the presence of renal artery stenosis. A renal/ aortic peak systolic velocity (PSV) ratio Ͼ3.5 and elevation of renal artery PSV Ͼ200 cm/s constitute significant stenosis, ie, Ͼ60%. Changes in antihypertensive therapy, including angiotensin converting enzyme inhibitors, were noted.
Statistical analysis. Data are expressed as median and range. The Fisher exact test was used for comparison of demographic data, preoperative risk factors, and renal artery patency between the two groups. Because SCr (mg/ dL) measurements in this cohort of patients were highly skewed, nonparametric analysis was used as appropriate. A repeated-measures analysis of variance model was also used to analyze change in SCr over time within and between groups. All tests were two-tailed, with P Ͻ .05 considered significant.
RESULTS
Patient demographic data, aneurysm size, and preoperative risk factors are listed in Table I . There was no significant difference between the two groups. Median infrarenal aortic neck length was 25 mm (range, 10-55 mm), and interrenal aortic diameter 22 mm (range, 15-26 mm) in group 1, compared with 25 mm (range, 15-65 mm) and 24 mm (18-27 mm), respectively, in group 2. Endograft deployment was technically successful in all patients. There were no intraoperative open conversion or perioperative deaths. One patient in group 1 had previously undergone nephrectomy because of renal cell carcinoma. Six patients (three in each group) had a history of renal artery stenosis and stent insertion before EVAR, but their SCr and blood pressure were stable preoperatively. Four other patients (two in each group) had unilateral significant renal artery stenosis (Ͼ50%) but normal preoperative SCr and blood pressure. In one patient an attempt to stent the stenosed renal artery during EVAR was unsuccessful. In one patient in group 2 the right renal artery was inadvertently partially covered by the graft fabric.
At median follow-up of 12 months (range, 1-36 months), hypertension had not developed in any patients, and none required intensification of anti-hypertension therapy. Seven patients underwent postoperative duplex US scanning in addition to CT, because intravenous contrast material was not used because of renal insufficiency. In the 6 patients with renal artery stenosis with a stent inserted before EVAR, neither significant change in SCr nor renal artery disease progression was noted during follow-up. In group 1 (infrarenal fixation), there were 126 renal arteries in 55 patients. No patients had main renal artery occlusion (Table II) . In two patients an accessory renal artery was covered intentionally, and follow-up CT scans showed renal polar atrophy but no significant change in postoperative SCr. The two patients with preoperatively stenosed renal arteries (Ͼ50%) showed no progression of stenosis during follow-up.
In group 2 (suprarenal fixation), there were 71 renal arteries in 32 patients. In the two patients with asymptomatic renal artery stenosis preoperatively, renal artery occlu-sion associated with renal atrophy was demonstrated on contrast-enhanced CT scans at 1-month follow-up ( Fig 2) , and SCr was persistently elevated compared with preoperative concentration, from 1.3 mg/dL to 1.8 mg/dL, and 1.3 mg/dL to 2.1 mg/dL, respectively. In the patient with the right renal artery inadvertently covered by a malposi- (Fig 3) . In group 1 there was a significant increase in median SCr at 1 month (P ϭ .05), 6 months (P Ͻ .001), and 12 months (P ϭ .001), compared with preoperative levels. In group 2 there was a small but significant increase in SCr at 1 month (1.1 mg/dL [range, 0.8-5.6 mg/dL]; P ϭ .035). Although median SCr was lower than the preoperative value, a larger proportion of patients (47%) had increased SCr, as compared with 31% of patients with decreased SCr, and the magnitude of the increases was greater than the decreases, hence an overall significant increase in SCr at 1 month (mean SCr, 1.35 mg/dL vs 1.15 mg/dL). However, this increase was small, and the evidence was not overwhelming. At 6 and 12 months, there was no statistically significant increase in SCr (1.2 mg/dL [range, 0.8-2.1 mg/dL], P ϭ .29, and 1.3 mg/dL [range, 0.7-3.2 mg/dL], P ϭ .07, respectively). If the two patients with preexisting renal artery stenosis with subsequent occlusion and the patient with inadvertent renal artery coverage were excluded from the analysis, median SCr did not change significantly after EVAR in group 2. With repeated-measures analysis of variance model, change in SCr over time was not significantly different between the two groups during the study period (P ϭ .408).
During follow-up there were 11 endoleaks (two type I, nine type II) in group 1 and nine in group 2 (all type II). In one patient in group 1 the stent graft migrated; endovascular intervention failed, and late open conversion was necessary. Another patient underwent late open conversion because of endotension and increasing aneurysm size. In one patient in group 2 a suprarenal aneurysm developed adjacent to the suprarenal bare stent of the endograft and required open repair. Another patient had a myocardial infarction shortly after EVAR, and acute chronic renal failure developed, which improved with medical treatment without the need for dialysis. SCr increased from 2.3 mg/dL preoperatively to 5.6 mg/dL at 1 month.
DISCUSSION
Unfavorable anatomy of the proximal aortic neck is one of the most common causes of patient exclusion from EVAR. Anchoring the endograft in the undilated suprare-nal aorta with an uncovered stent to improve proximal fixation may extend the indication for EVAR to include this subgroup of patients. Earlier studies support the renal safety of suprarenal endograft fixation [4] [5] [6] [7] [8] (Table III) . However, long-term safety associated with placing an uncovered stent across the renal artery ostia remains a major concern.
Malina et al 4 reported 18 patients with suprarenal fixation of a Gianturco Z stent graft with median follow-up of 6 months. Using CT, angiography, and SCr measurement, they found no evidence of renal artery compromise or deterioration of renal function, but CT scans did show a small infarct in one kidney. Marin et al 5 compared findings in 37 patients with suprarenal endograft fixation with those in 16 patients with infrarenal fixation of a homemade endograft constructed from a Palmaz balloon-expandable stent and an expandable polytetrafluoroethylene graft. At mean follow-up of 10 months there was no significant change in SCr or hypertension status in these patients. Angiograms, CT scans, and duplex US scans did not show significant renal artery compromise when the endograft was properly placed. In two patients follow-up CT scans demonstrated segmental renal artery infarction but no change in renal function. Lobato et al 6 studied 35 patients who underwent EVAR with suprarenal fixation with three types of endograft. At median follow-up of 11 months, 14% of patients had transiently elevated SCr after endografting, but there was no significant difference between preprocedural and postprocedural SCr. Bove et al 7 reported 28 patients with suprarenal endograft fixation with median follow-up of 6 months. Five patients with elevated preoperative SCr had persistent elevation postoperatively, and three had a greater than 20% increase from preoperative levels. One patient with normal preoperative renal function had persistently elevated SCr postoperatively. No localized These studies suggest that suprarenal endograft fixation is benign, and the results of our study appear to corroborate this observation. With repeated measures of analysis of variance, we found no significant difference in the change over time in SCr during the 12 months of follow-up between suprarenal and infrarenal endograft fixation. Of the 87 patients included in the analysis, 13 patients (15%) had preoperative SCr Ն1.3 g/dL. The suprarenal group had higher preoperative SCr, but this simply reflects the nonrandomized nature of the study. Over the study period, SCr increased in both groups of patients, although it did not reach statistical significance in the suprarenal group. The infrarenal group demonstrated a significant increase in SCr, but the increases were small, and clinically, median SCr was within the normal range. This is comparable to findings of Carpenter et al, 13 who reported a 20% incidence of baseline renal insufficiency in patients undergoing EVAR. In 24% of their patients SCr increased above baseline after endografting, independent of use of infrarenal or suprarenal fixation. Many factors may be responsible for the increase in SCr after endografting. Contrast-induced renal insufficiency has been well documented, and repeated use during follow-up may contribute to increased SCr. 13 Patients with preexisting renal insufficiency are at particular risk, and alternative follow-up imaging techniques or strategies for reducing adverse renal events should be considered in this group of patients. Thromboembolism during endografting may also be a contributing factor to renal impairment. A small amount of thrombus in the aortic neck might be present and not detected at preoperative imaging. Manipulation of the endograft within the aortic neck and aneurysm sac, balloon expansion of the proximal stent, or maneuvers in repositioning of the endograft may result in embolism or thrombosis of the renal arteries. Findings of punctate renal infarctions on follow-up CT scans have been noted in various studies, suggesting atheroembolic sequelae of EVAR. 9 The two patients in our series in whom renal artery occlusion developed had preexisting renal artery stenosis Ͼ50%. Whether occlusion was a result of the struts of the uncovered stent crossing the renal artery ostia or due to progression of the atherosclerotic disease per se is difficult to determine. Results from earlier studies are inconclusive. In the study by Marin et al, 5 18 patients with preexisting significant renal artery stenosis underwent suprarenal endograft fixation and did not demonstrate any disease progression. In contrast, Lobato et al 6 reported that in one of five patients with preexisting unilateral renal artery stenosis Ͼ60% the disease progressed to 99% stenosis at 4 months after suprarenal fixation. Similarly, Bove et al 7 reported that one of eight patients with preoperative evidence of renal artery atherosclerotic disease had progression of renal artery stenosis from 30% to 60% 12 months after endografting. In another patient with normal renal artery preoperatively, stenosis Ͼ60% had developed at 1-month follow-up. Although stenosis progression may be due to the natural   Table III . Summary of published series of patients with suprarenal endograft fixation history of the renal artery disease, it is possible that the suprarenal stent may have accelerated the disease progression, because renal blood flow must be maintained via stent interstices. The numbers of patients affected in these series, including the current study, were small, and no conclusion can be drawn regarding the possible role of suprarenal fixation on progression of renal atherosclerotic disease. Whether these lesions should be treated preoperatively or during EVAR needs further study.
Another factor that may have an important influence on renal artery patency is the type of stent used for proximal fixation. In a porcine model, Birch et al 14 demonstrated that development of disorganized acellular matrix causing partial renal ostial occlusion depends on stent type. A variety of stents were used for proximal fixation in clinical studies, which may account for the difference observed in renal artery patency. Conclusions drawn from the data in these studies should be interpreted with caution.
In the current study, SCr measurement was used to determine functional status of the kidneys after EVAR. We admit this is not a sensitive method for detecting renal dysfunction. Significant renal parenchymal tissue loss or renal artery stenosis can occur without a significant effect on SCr. Measurement of creatinine clearance may provide more useful information regarding functional status of the kidneys, but it was not part of our surveillance protocol. Nevertheless, we retrospectively estimated creatinine clearance preoperatively and at 12 months post-EVAR in the two groups of patients with the Cockcroft-Gault formula. 15 There was no significant difference in change in creatinine clearance over the 12 months between the two groups (P ϭ .121), consistent with SCr results (Fig 4) . In addition, angiography and contrast-enhanced CT may not be ideal methods for evaluation of renal artery anatomy and patency after EVAR. Intrarenal color duplex US scanning has been suggested as a simple and affordable screening tool, but it is operator-dependent and technically difficult. 16 Intravascular US is a more reliable and accurate method for assessing the renal arteries, but it is more invasive and not practical as a surveillance tool. Magnetic resonance angiography has been used to diagnose renal artery stenosis, but its safety in patients with endografts is unknown. 17 Further studies are required to determine the ideal surveillance tool for renal artery luminal configuration and renal circulation in patients with suprarenal endograft fixation.
In conclusion, our experience with suprarenal endograft fixation with the Zenith device, based on intermediate follow-up, suggests that renal dysfunction and renal artery occlusion are uncommon in patients with no preexisting significant renal artery stenosis. However, it should be noted that this is a retrospective cohort study of a single institutional experience and that the number of patients in the suprarenal group was relatively small. Although we found no significant effect of suprarenal stenting on postoperative renal function and renal artery patency, renal artery occlusion occurred in the two patients who had preexisting renal artery stenosis in the suprarenal group. It is advisable to exercise caution when suprarenal endograft fixation is considered in these patients. A larger study with longer follow-up is necessary to assess the overall effects of various endografts on renal artery patency and renal function, especially in the subgroup of patients with significant renal atherosclerotic disease.
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